Plandai Biotechnology Inc (OTCMKTS:PLPL) And Generex Biotechnology Corporation (OTCMKTS:GNBT) Issues Promising PRs

Plandai Biotechnology Inc (OTCMKTS:PLPL) and Generex Biotechnology Corporation (OTCMKTS:GNBT) are the two OTC traded stocks that have been the center of attraction after they issued promising PRs. Plandai reported an amendment to its preciously finalized deal with USN Worldwide. Under the new amended deal with USN, it will now expand its Phytofare® sales to USN […]

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s EYLEA Gets FDA Breakthrough Designation

Boston, MA 09/16/2014 (wallstreetpr) – Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to EYLEA. The drug targets patients with diabetic macular edema (DME) for the treatment of diabetic retinopathy. The Breakthrough Therapy designation was triggered by the positive results obtained from two late-stage trials of the […]

Sanofi SA (ADR) (NYSE:SNY) And Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reported Success In Phase II Study With Rheumatoid Arthritis Drug

Boston, MA 06/12/2014 (wallstreetpr) – Sanofi SA (ADR) (NYSE:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced successful results from a Phase III study of experimental drug sarilumab in treating rheumatoid arthritis (RA) in patients who had previously shown no response to  methotrexate (MTX) treatment. The pharmaceutical companies presented their new data which demonstrated that sarilumab is capable […]